Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/14/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts